SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA ), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCsTM), today announced the appointment of John B.
Moriarty, Jr. , J.D.
, as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth.
Mr. Moriarty succeeds John W. Wallen III, Ph.
D., J.D.
, who served as General Counsel since 2019 and has been head of intellectual property since Avidity's inception in 2014. Dr. Wallen will remain with the company through year-end and will transition as a consultant.
"We are pleased to have John join our leadership team. His extensive legal expertise and experience in leading biopharmaceutical companies through transformational growth will be instrumental as we continue to advance our three clinical development programs for the treatment of three distinct rare muscle diseases, expand our pipeline utilizing our broad AOC platform and build an integrated global organization," said Sarah Boyce , president and chief executive officer. "On behalf of our Avidity team, we extend our deepest gratitude to Dr.
Wallen for his exceptional leadership and substantial contributions since our inception, including establishing a solid legal.